Todays Times Business 16 Feb 2018 An Oxford University spin-off that specialises in gene therapy applications has won a $100 million contract from Bioverativ, an American company specialising in treatments for haemophilia.Shares in Oxford Biomedica rose 11.7 per cent to 12p after it announced the deal, under which it will receive $5 million immediately and milestone payments worth up to $100 million.It is the second major deal in seven months for the company, which was spun off from Oxford University in 1995, early in the gene therapy revolution. It floated on the Alternative Investment Market in 1996, moving to the official list of the London Stock Exchange in 2001.Last July it signed a three-year deal that could be worth more than $100 million with the Swiss drugmaker Novartis to supply material for a new treatment for leukaemia.In both deals Oxford Biomedica will supply lentivectors, which are used to insert genes into human cells. Oxford Biomedica is also in line to receive royalties on sales of the companys haemophilia products.Analysts at Peel Hunt said yesterdays deal cemented their view that Oxford Biomedicas technology was at the forefront of the gene and cell therapy revolution.[link]
The future is ours . Sorry once again posted wrong post Sorry ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------I know many on this board were very annoyed when the present board decided to stop chasing rain bows, and started concentrating on producing a product that could bring in an income, to ensure OXB could survive.The Bod that followed and those who put their own cash into this company I believe stopped OXB going bust, and they should be thanked for that, and yes it did meant OXB had to change direction , from the days of Professor Kingsman and his wife, who founded this company, they did such a great job for OXB in the early years ,especially with their expertise in Biologics and DNA ,and yes they were trail blazers that gave OXB a future , and again, we have to thank them for what they did for the company while they were in charge ,but they were only interested in R/D, and that did not produce the revenues we needed as a company to keep going .Just looking back at the 2000 accounts, back then ,OXB had only just started clinical trials with MetXia, and Tro- Vax they were just about to enter clinical development, and OXB were still awaiting approval for the phase 1/11 trial for colorectal cancer, neither product produced a penny in revenue for OXB , so both products have now been put on hold, or dropped, and after twenty years of R/D and hundreds of millions of pounds spent on them, they have produced nothing in revenue .The company had to find another way forward, so they moved away from R/D and expanded into the manufacturing of our own Lentivector, and its already paying us back ,and it will continue to do so for the foreseeable future ,OXB plant is the only one in the world that can produce this product ,yes there are other vectors out there ,but they are owned by the big pharmer,s ,and they need everything they can produce for their own products ,that leaves OXB as the only independent company in this area of expertise to take up the slack from all the other companies out there, who require this kind of technology .The Novates contract alone will put OXB into profit, it's estimated their contract alone is worth around £100m, and could be as high as £1billion over 10 years, that means OXB will continue to grow over that time, and is where we will get the cash to fund our future R/D , I/E cash to support products such as Tro -Vax .I personally can't see any reasons why O.X.B should return to its shareholders for more cash, and that's why the Government are now backing OXB, as it needs companies like ours to help new companies get established in the UK they also to see OXB as a way of helping start-ups in this industry, that's why they are backing OXB with grants ,and appointing them as their manufacturing partner in Biotech , and I Like Crisisurfer believe this is why the value in OXB is now locked in ,and it will grow even stronger as new contracts are signed .Genomics is the future and the government know that, and they are determined that the UK will stay at the forefront of the competition ,and to prove that, a new Government backed project for new Bio start-ups is being built in Reading right now , its near junction 12 of the M4, and the university of Reading are backing the project, and will help those who want to take space there , already there are two very large blocks of new labs being built and will accommodate many new Bio start-ups in the future ,all of who will need our product and advice in the future .The future is ours BE HAPPYDAVE
Re: Good news, but still jam tomorrow I know many on this board were very annoyed when the present board decided to stop chasing rain bows, and started concentrating on s producing a product that could bring in an income, to ensure OXB could survive .This Bod, and those who put their own cash into this company to stop it going bust should be thanked, even though it meant OXB had to change from the days of Professor Kingsman and his wife who founded this company, and did such a great job in the early day with their expertize in Biologics they were trail blazers back then, and we have to thank them as well for what they did ,but they were only interested in R/D and that did not produce the revenues to keep OXB afloat .Just looking back at the year 2000 accounts, they had only just started clinical trials with MetXia, and Tro- Vax was just about to enter clinical development ,and was awaiting approval for a phase 1/11 trial in colorectal cancer, and neither product produced a penny in revenue, so both products have now been put on hold, or dropped , after twenty years of R/D and hundreds of millions of pounds spent on them. The company now has moved on from being a R/D company , but has expanded into the manufacturing of Lentivector its all ready paying back some of our investment ,and it will continue to do so ,as its the only plant in the world that can produce this product ,yes there are other vectors out there ,but they are owned by the big pharmer,s who need what production they have for their own products ,leaving OXB as the only independent company in this area of expertize to take up the slack from all the other companies out there that require this technology .Novates alone will put OXB into profit as it's estimated their contract alone is worth some where between £100m and £1 billion when in full production ,that means OXB will continue to grow over the next 10 years , and that is where we will get the cash to fund our future R/D for products such as Tro -Vax . I personally can't see any further reasons for O.X.B to return to it shareholders asking for more cash,that's why the Government are now backing OXB and are backing both the company and it's now how because they to see OXB as the for runner to other start ups in this industry and that's why they are backing OXB with grants ,and Like Crisisurfer I also believe that the value in OXB is now locked in ,and it will grow stronger as new contracts are signed .Genomics is the future, and the government know that ,and they are determined that the UK stays in front of the competition .And to prove that, a new Government backed project for new Bio start ups is being built in Reading, near to junction 12 of the M4, the university of Reading are also backing the project and will help those who take space , all ready there are two very large blocks of labs being built ,this will accommodate many new Bio start ups ,who will also need our product .The future is good for OXB BE HAPPYDAVE
Re: Good news, but still jam tomorrow Hmmmmm...yes Russian Oligarchs might learn to fly? But yes I doubt it too.What has surprised me is that for this company the UK government has learnt to fly. Support in the form of loans and grants at vital times, especially recently, as OXB face up to the existential challenge of scaling up and industrialising the processes required.OXB is one of the only places in the world that can do this, and UK Gov get that!Therefore assigning value to the company is more difficult than most other pharma including start ups! For example how many start ups have proof of concept for such an industry changing technology, and control over the manufacturing technology, which is in itself a potentially huge asset?OXB could be taken over, but I hope not. If they survive take over risks then they could start to acquire significant long term value from here.One thing is for sure. Their value is now tied at the hip with emergence of a whole new pharma sector and frontier. OXB helped makes this happen and I for one am sure glad that they are at the front of it. I am also certain that conventional analysis doesnt make it easy to value this company. I suspect however that (barring unforeseen calamity) the current value is now locked in, and for me that makes it a buy! Any company that has changed medicine in the face of Big Pharma has already punched above its weight! My gut instinct, based on the above, is that OXB will now go North from here. GLA
looks like China has just joined the Car-t race [link]
Re: Good news, but still jam tomorrow Yes S17 I would agree that from an altruistic viewpoint it is excellent that money has been provided for OXB in their past fundraisings and that more will likely be provided in future fundraisings. I wish that wealthy oligarchs from Russia and the middle east would put their money into worthwhile ventures such as this rather than football clubs! OXB's trailblazing work has achieved a huge amount not only from a scientific viewpoint, but also in terms of future benefits for mankind. I think your timescale for potential benefits to shareholders of about 5 to 10 years is about right, unless they (or their potential spin-off vehicles) can raise significant amounts of money to accelerate product development.
Re: Good news, but still jam tomorrow About 1998-9 I warned about short termism and said give it 10 years. I'd not have expected it to take 20+ and counting, but what a tribute to those who've managed to convince so many to keep on stumping up cash to fund the annual losses. In the meantime we seem to be making significant scientific progress to help mankind.I'm hoping to live long enough to benefit financially, but in the meantime I'm content to have provided some support from the very early days. Give it another 5-10 years.
Re: Good news, but still jam tomorrow We thought you were the specialist.
Good news, but still jam tomorrow Another big agreement for OXB but still following the pattern of a small up front payment with enormous amounts of jam tomorrow. This, of course, is the nature of OXB's business model but it is not a very attractive one. The financial upside to the products it is developing do little more than support its running costs. However I am beginning to get a bit more interested as I think the company is reaching a position where it can at least sustain itself, but if anyone knows when it will reach a position of sustainable profit growth, please let me know!
Car-t cells and HIV [link]
Re: CART-T pricing Indeed, it's been a roller coaster ride for long term holders, a bit touch and go on a few occasions, but I think there is no stopping us now, leaders in the field with lots of manufacturing capability we should see our rewards shortly, and fantastic treatments coming on stream for awful diseases as a bonus!
Another huge deal [link] Wow
CART-T pricing [link] article questioning the pricing of Kymriah.Exciting times ahead for OXB assuming Novartis get approval and great to see such impressive results todate in the treatment of this type of cancer.Having bought shares in OXB some as high as 49p and others as low as 3p (average now 12p) I'm very close to finally seeing a paper profit having held for almost 15 years. Best wishes those who have kept the faith and to all who have contributed to this discussion board here over the years.
Re: CAR-T interview On BBC Hi DG;Yes agree with you that the companies behind the delivery system never gets the credit they deserve. I felt the interview was half way there. I sometimes think OXB are pretty sleepy when it comes to PR! Regarding OT, yes were still going and growing. The website is at www.blue-sky-therapies.com . Were really Devon and Cornwall based and do mostly sensory processing and neurodevelopmental paediatrics, but adult referrals are increasing. Do feel free to pass on details or get in touch via website. Wed be happy to help in anyway we can even if its just a chat and pointers to what the opportunities are like in the private sector.Thanks also for all your great posts. Theyve kept me going on this share when patience has been at a premium CS
Re: CAR-T interview On BBC Hi Crisisurfer they never talk about OXB when they talk about cart T ,I have read hundreds of reports about Cart T over the years ,but non of them mention the delivery system , it can be very frustrating at times as they seem to think they own the system. And to be honest they might as well ,as I have not seen any body else signing contracts recently to use our Lentifactor , which seems a bit odd to me ,as the press keep telling every one, that there is shortage of systems like Lentifactor out there and because of that shortage its holding gene therapy back ,yet OXB say, they would be able to take on more work should any body want to use their services strange that .. There must be gremlins in the water BE HAPPYDAVE ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------Crissis surfer Some time ago you spoke to me about your O/T agency ? are you still running it ? if so, my daughter would be interested in joining you .Do you have any work in the south of England ? she was working in children's services doing full assessments and grants for planning, she is also a registered trainer regarding other staff ,and equipment including hoists . BE HAPPYDAVE .